Literature Review of Safety Event Reporting in Observational Studies: Challenges Extrapolating across Comparable Products
Nirmatrelvir/ritonavir (PAXLOVID<sup>TM</sup>, Pfizer) is an anti-infective inhibiting CYP3A4 indicated for the treatment of COVID-19 in adults at increased risk of severe COVID-19. As a newly approved product, PAXLOVID has limited safety information regarding rare events and serious adv...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2023-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|